JUBLPHARMA.NS Balance Sheet
Jubilant Pharmova Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 8 years on file
(FY2017-18 to FY2025-26)
· fetched 2026-08-23 23:33
| Line item | FY2017-18 | FY2019-20 | FY2020-21 standalone basis | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|---|
| Property, Plant and Equipment | N/A | N/A | N/A | N/A | ₹2,297.53 Cr. | ₹2,157.80 Cr. | ₹2,132.30 Cr. | ₹3,509.60 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | N/A | N/A | N/A | N/A | ₹773.25 Cr. | ₹1,252.30 Cr. | ₹2,714.70 Cr. | ₹2,961.50 Cr. | CapitalWorkInProgress |
| Goodwill | N/A | N/A | N/A | N/A | ₹2,428.59 Cr. | ₹2,463.90 Cr. | ₹2,541.00 Cr. | ₹2,826.10 Cr. | Goodwill |
| Other Intangible Assets | N/A | N/A | N/A | N/A | ₹457.14 Cr. | ₹192.50 Cr. | ₹181.40 Cr. | ₹197.70 Cr. | OtherIntangibleAssets |
| Non-current Investments | N/A | N/A | N/A | N/A | ₹32.79 Cr. | ₹34.40 Cr. | ₹36.00 Cr. | ₹60.60 Cr. | NoncurrentInvestments |
| Other Non-current Assets | N/A | N/A | N/A | N/A | ₹146.81 Cr. | ₹460.10 Cr. | ₹366.70 Cr. | ₹490.40 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | N/A | N/A | N/A | N/A | ₹7,394.25 Cr. | ₹7,672.40 Cr. | ₹9,179.20 Cr. | ₹11,413.40 Cr. | NoncurrentAssets |
| Inventories | N/A | N/A | N/A | N/A | ₹1,380.53 Cr. | ₹1,289.60 Cr. | ₹1,129.20 Cr. | ₹1,231.50 Cr. | Inventories |
| Trade Receivables | N/A | N/A | N/A | N/A | ₹961.24 Cr. | ₹915.90 Cr. | ₹891.50 Cr. | ₹1,069.60 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | N/A | N/A | N/A | N/A | ₹1,013.92 Cr. | ₹956.40 Cr. | ₹1,088.30 Cr. | ₹1,267.10 Cr. | CashAndCashEquivalents |
| Current Investments | N/A | N/A | N/A | N/A | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | CurrentInvestments |
| Other Current Assets | N/A | N/A | N/A | N/A | ₹264.61 Cr. | ₹205.00 Cr. | ₹220.60 Cr. | ₹249.00 Cr. | OtherCurrentAssets |
| Total Current Assets | N/A | N/A | N/A | N/A | ₹3,762.40 Cr. | ₹3,632.20 Cr. | ₹3,509.70 Cr. | ₹4,109.30 Cr. | CurrentAssets |
| Total Assets | N/A | N/A | N/A | N/A | ₹11,156.65 Cr. | ₹11,548.50 Cr. | ₹12,756.40 Cr. | ₹15,522.70 Cr. | Assets |
| Equity Share Capital | N/A | N/A | N/A | N/A | ₹15.91 Cr. | ₹15.80 Cr. | ₹15.80 Cr. | ₹15.80 Cr. | EquityShareCapital |
| Other Equity | N/A | N/A | N/A | N/A | ₹5,383.37 Cr. | ₹5,418.10 Cr. | ₹6,239.10 Cr. | ₹7,077.00 Cr. | OtherEquity |
| Equity Attributable to Owners | N/A | N/A | N/A | N/A | ₹5,399.28 Cr. | ₹5,433.90 Cr. | ₹6,254.90 Cr. | ₹7,092.80 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | N/A | N/A | N/A | ₹-7.49 Cr. | ₹-12.80 Cr. | ₹-16.30 Cr. | ₹2.80 Cr. | NonControllingInterest |
| Total Equity | N/A | N/A | N/A | N/A | ₹5,391.79 Cr. | ₹5,421.10 Cr. | ₹6,238.60 Cr. | ₹7,095.60 Cr. | Equity |
| Long-term Borrowings | N/A | N/A | N/A | N/A | ₹3,110.36 Cr. | ₹3,167.10 Cr. | ₹2,150.30 Cr. | ₹2,971.70 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | N/A | N/A | N/A | N/A | ₹3,992.46 Cr. | ₹4,238.40 Cr. | ₹4,353.20 Cr. | ₹5,888.20 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | N/A | N/A | N/A | N/A | ₹299.72 Cr. | ₹247.00 Cr. | ₹286.60 Cr. | ₹247.80 Cr. | BorrowingsCurrent |
| Trade Payables | N/A | N/A | N/A | N/A | ₹821.32 Cr. | ₹856.30 Cr. | ₹1,004.80 Cr. | ₹1,234.10 Cr. | TradePayablesCurrent |
| Other Current Liabilities | N/A | N/A | N/A | N/A | ₹121.78 Cr. | ₹163.20 Cr. | ₹202.10 Cr. | ₹340.30 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | N/A | N/A | N/A | N/A | ₹1,772.40 Cr. | ₹1,889.00 Cr. | ₹2,164.60 Cr. | ₹2,538.90 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | N/A | N/A | N/A | N/A | ₹11,156.65 Cr. | ₹11,548.50 Cr. | ₹12,756.40 Cr. | ₹15,522.70 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from JUBLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).